Shares of Eli Lilly & Co. (LLY) were down more than 2% Friday after the pharmaceutical company announced that the 澳洲幸运5官方开奖结果体彩网:Food and Drug Administration (FDA) wants more information abo🌱ut its experimental Alzheimer’s treatment, donanemab, which will delay its release.

The company said the FDA expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to look into the Phase 3 trial results of donanemab. It explained the committee would be discussing “the efficacy and safety of donanemab in early symptomatic Alzheimer's disease.”

Lilly added that the date of the advisory group meeting has yet to be determined by the FDA, so anticipated approval action by officials on donanemab won’t happen until after the first quarter.

Anne White, executive vice president of Lilly and president of Lilly Neuroscience, said the drug maker was surprised by the FDA decision, and is “confident in donanemab's potential to offer very meaningful benefits to people with early symptomatic Alzheimer's disease.”

Lilly said that the FDA’s move won't affect the company’s 2024 澳洲幸运5官方开奖结果体彩网:financial guidance. 

The news boosted shares of Biogen Inc. (BIIB) Friday, because donanemab would be a rival to its own Alzheimer’s drug, Leqembi. Biogen wasꦑ up almost 2.5% to $224.83 at around 2:30 p.m. ET.

Eli Lilly shares w🐷ere down 2.2% at $763.00. Despite the decline, the stock has gained nearly 30% since the sta꧋rt of the year.